A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia

NCT05232149 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immune Thrombocytopenia

Interventions

DRUG: Orelabrutinib( lower dose)
DRUG: Orelabrutinib( higher dose)

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.